{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:34:45Z","timestamp":1791434085458,"version":"4.3.3"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society\/Alpe d\u2019HuZes","doi-asserted-by":"publisher","award":["A6C\/6253"],"award-info":[{"award-number":["A6C\/6253"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.breast.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T17:13:46Z","timestamp":1544116426000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"44","author":[{"given":"Delal","family":"Akdeniz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjanka K.","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Seynaeve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"McCool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Giardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"van den Broek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hauptmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewout W.","family":"Steyerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje J.","family":"Hooning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.breast.2018.11.005_bib1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Canc"},{"issue":"5","key":"10.1016\/j.breast.2018.11.005_bib2","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1200\/JCO.2015.62.3942","article-title":"Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1\/2 mutation carriers","volume":"34","author":"van den Broek","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.breast.2018.11.005_bib3","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1200\/JCO.2009.24.2495","article-title":"Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2","volume":"28","author":"Malone","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.breast.2018.11.005_bib4","series-title":"Dutch guideline (hereditary) breast cancer version 2.0","year":"2012"},{"key":"10.1016\/j.breast.2018.11.005_bib5","series-title":"Surgery to reduce the risk of breast cancer. 2013 August 12","author":"Institute","year":"2013"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib6","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ijc.29032","article-title":"Improved overall survival after contralateral risk-reducing mastectomy in BRCA1\/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis","volume":"136","author":"Heemskerk-Gerritsen","year":"2015","journal-title":"Int J Canc"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/SLA.0000000000001698","article-title":"Growing use of contralateral prophylactic mastectomy despite no improvement in long-term survival for invasive breast cancer","volume":"265","author":"Wong","year":"2017","journal-title":"Ann Surg"},{"issue":"7","key":"10.1016\/j.breast.2018.11.005_bib8","doi-asserted-by":"crossref","first-page":"e262","DOI":"10.1016\/S1470-2045(13)70047-0","article-title":"Contralateral risk-reducing mastectomy in sporadic breast cancer","volume":"14","author":"Murphy","year":"2013","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-013-2643-6","article-title":"Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research","volume":"140","author":"Tracy","year":"2013","journal-title":"Breast Canc Res Treat"},{"issue":"6","key":"10.1016\/j.breast.2018.11.005_bib10","doi-asserted-by":"crossref","first-page":"373","DOI":"10.7326\/0003-4819-159-6-201309170-00003","article-title":"Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey","volume":"159","author":"Rosenberg","year":"2013","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.breast.2018.11.005_bib11","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1245\/s10434-011-1914-x","article-title":"Perceptions of contralateral breast cancer: an overestimation of risk","volume":"18","author":"Abbott","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.breast.2018.11.005_bib12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/JCO.2012.43.2013","article-title":"Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women's Environmental Cancer and Radiation Epidemiology Study","volume":"31","author":"Reiner","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"35","key":"10.1016\/j.breast.2018.11.005_bib13","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1200\/JCO.2008.19.9430","article-title":"Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"27","author":"Graeser","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.breast.2018.11.005_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120832","article-title":"Survival after locoregional recurrence or second primary breast cancer: impact of the disease-free interval","volume":"10","author":"Witteveen","year":"2015","journal-title":"PloS One"},{"issue":"25","key":"10.1016\/j.breast.2018.11.005_bib15","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1200\/JCO.2012.47.8313","article-title":"Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"31","author":"Phillips","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10549-015-3419-y","article-title":"Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry","volume":"151","author":"Menes","year":"2015","journal-title":"Breast Canc Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120189","article-title":"Worse breast cancer prognosis of BRCA1\/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis","volume":"10","author":"van den Broek","year":"2015","journal-title":"PloS One"},{"issue":"11","key":"10.1016\/j.breast.2018.11.005_bib18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1093\/oxfordjournals.aje.a116237","article-title":"Methods for trend estimation from summarized dose-response data, with applications to meta-analysis","volume":"135","author":"Greenland","year":"1992","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.breast.2018.11.005_bib19","unstructured":"Netherlands Cancer Registry. www.iknl.nl."},{"issue":"6","key":"10.1016\/j.breast.2018.11.005_bib20","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/ije\/dyu202","article-title":"Incidence of metachronous contralateral breast cancer in Denmark 1978-2009","volume":"43","author":"Rasmussen","year":"2014","journal-title":"Int J Epidemiol"},{"issue":"4","key":"10.1016\/j.breast.2018.11.005_bib21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0360-3016(03)00203-7","article-title":"Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study","volume":"56","author":"Gao","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib22","doi-asserted-by":"crossref","first-page":"R38","DOI":"10.1186\/bcr2860","article-title":"Second malignancies in breast cancer patients following radiotherapy: a study in Florence, Italy","volume":"13","author":"Zhang","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jrsm.12","article-title":"A\u00a0basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"issue":"4","key":"10.1016\/j.breast.2018.11.005_bib24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1604700","article-title":"Extending aromatase-inhibitor adjuvant therapy to 10 years","volume":"375","author":"Goss","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.breast.2018.11.005_bib26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejca.2016.05.010","article-title":"Contemporary risks of local and regional recurrence and contralateral breast cancer in patients treated for primary breast cancer","volume":"63","author":"Aalders","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.breast.2018.11.005_bib27","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1186\/s40064-015-1642-y","article-title":"Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: Results from the WECARE study","volume":"4","author":"Sisti","year":"2015","journal-title":"SpringerPlus"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib28","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.canep.2014.11.007","article-title":"Survival and relapse free period of 2926 unselected older breast cancer patients: a FOCUS cohort study","volume":"39","author":"Kiderlen","year":"2015","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10549-015-3597-7","article-title":"Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age","volume":"154","author":"Drooger","year":"2015","journal-title":"Breast Canc Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2018.11.005_bib30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10689-015-9825-9","article-title":"Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis","volume":"14","author":"Basu","year":"2015","journal-title":"Fam Cancer"},{"issue":"11","key":"10.1016\/j.breast.2018.11.005_bib31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.annepidem.2014.08.003","article-title":"Risk of contralateral breast cancer after tamoxifen use among Danish women","volume":"24","author":"Mellemkjaer","year":"2014","journal-title":"Ann Epidemiol"},{"issue":"5","key":"10.1016\/j.breast.2018.11.005_bib32","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/bjc.2014.306","article-title":"Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy","volume":"111","author":"Kriege","year":"2014","journal-title":"Br J Canc"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10549-014-3026-3","article-title":"Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"146","author":"Gronwald","year":"2014","journal-title":"Breast Canc Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib34","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10549-014-3157-6","article-title":"Metabolic syndrome and outcomes following early-stage breast cancer","volume":"148","author":"Calip","year":"2014","journal-title":"Breast Canc Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1634\/theoncologist.2012-0315","article-title":"Elderly postmenopausal patients with breast cancer are at increased risk for distant recurrence: a tamoxifen exemestane adjuvant multinational study analysis","volume":"18","author":"van de Water","year":"2013","journal-title":"Oncol"},{"issue":"5","key":"10.1016\/j.breast.2018.11.005_bib36","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/jrr\/rrt009","article-title":"Second malignancies following conventional or combined (2)(5)(2)Cf neutron brachytherapy with external beam radiotherapy for breast cancer","volume":"54","author":"Valuckas","year":"2013","journal-title":"J\u00a0Radiat Res"},{"issue":"4","key":"10.1016\/j.breast.2018.11.005_bib37","doi-asserted-by":"crossref","first-page":"R57","DOI":"10.1186\/bcr3451","article-title":"Change of mammographic density predicts the risk of contralateral breast cancer--a case-control study","volume":"15","author":"Sandberg","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/jrr\/rrs087","article-title":"Radiation therapy following surgery for localized breast cancer: outcome prediction by classical prognostic factors and approximated genetic subtypes","volume":"54","author":"Pacelli","year":"2013","journal-title":"J\u00a0Radiat Res"},{"issue":"25","key":"10.1016\/j.breast.2018.11.005_bib39","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1200\/JCO.2012.46.1574","article-title":"Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: Results from international breast cancer study group trials VIII and IX","volume":"31","author":"Metzger-Filho","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.breast.2018.11.005_bib40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/jnci\/djt095","article-title":"Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE","volume":"105","author":"Mavaddat","year":"2013","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib41","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/bcr3378","article-title":"Mammographic density as a predictor of breast cancer survival: the Multiethnic Cohort","volume":"15","author":"Maskarinec","year":"2013","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib42","first-page":"95","article-title":"Immunohistochemically defined subtypes and outcome of apocrine breast cancer","volume":"13","author":"Dellapasqua","year":"2013","journal-title":"Clin Breast Canc"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib43","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.radonc.2013.06.028","article-title":"Influence of internal mammary node irradiation on long-term outcome and contralateral breast cancer incidence in node-negative breast cancer patients","volume":"108","author":"Courdi","year":"2013","journal-title":"Radiother Oncol"},{"issue":"14","key":"10.1016\/j.breast.2018.11.005_bib44","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/j.ejca.2013.04.028","article-title":"Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report","volume":"49","author":"Bernstein","year":"2013","journal-title":"Eur J Canc"},{"issue":"35","key":"10.1016\/j.breast.2018.11.005_bib45","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1200\/JCO.2012.42.7336","article-title":"CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer","volume":"30","author":"Weischer","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"28","key":"10.1016\/j.breast.2018.11.005_bib46","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.2011.39.3645","article-title":"Tumor stage affects risk and prognosis of contralateral breast cancer: Results from a large Swedish-population-based study","volume":"30","author":"Vichapat","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib47","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s10549-012-2183-5","article-title":"Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer","volume":"135","author":"Saltzman","year":"2012","journal-title":"Breast Canc Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib48","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10549-011-1820-8","article-title":"Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER","volume":"131","author":"Neta","year":"2012","journal-title":"Breast Canc Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib49","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","article-title":"Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: Results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA)","volume":"21","author":"Mavaddat","year":"2012","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"6","key":"10.1016\/j.breast.2018.11.005_bib50","doi-asserted-by":"crossref","first-page":"E64","DOI":"10.1684\/bdc.2012.1592","article-title":"Failure event types and prognostic factors after node-positive breast cancer in patients treated by adjuvant chemotherapy: impact on follow-up","volume":"99","author":"Filleron","year":"2012","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib51","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s10549-011-1743-4","article-title":"Body mass index and risk of second primary breast cancer: the WECARE Study","volume":"131","author":"Brooks","year":"2012","journal-title":"Breast Canc Res Treat"},{"issue":"13","key":"10.1016\/j.breast.2018.11.005_bib52","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ejca.2011.05.004","article-title":"Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways","volume":"47","author":"Vichapat","year":"2011","journal-title":"Eur J Canc"},{"issue":"9","key":"10.1016\/j.breast.2018.11.005_bib53","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/bjc.2011.120","article-title":"Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers","volume":"104","author":"Metcalfe","year":"2011","journal-title":"Br J Canc"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib54","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10549-010-1153-z","article-title":"Increased risk of contralateral breast cancers among overweight and obese women: a time-dependent association","volume":"126","author":"Majed","year":"2011","journal-title":"Breast Canc Res Treat"},{"issue":"13","key":"10.1016\/j.breast.2018.11.005_bib55","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1200\/JCO.2010.32.2933","article-title":"Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer","volume":"29","author":"Hackshaw","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10549-010-1137-z","article-title":"Risk of second breast cancer according to estrogen receptor status and family history","volume":"127","author":"Bouchardy","year":"2011","journal-title":"Breast Canc Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib57","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.bjc.6605434","article-title":"Relation of risk of contralateral breast cancer to the interval since the first primary tumour","volume":"102","author":"Rubino","year":"2010","journal-title":"Br J Canc"},{"key":"10.1016\/j.breast.2018.11.005_bib58","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1186\/1471-2407-10-697","article-title":"Separate and combined analysis of successive dependent outcomes after breast-conservation surgery: recurrence, metastases, second cancer and death","volume":"10","author":"Rondeau","year":"2010","journal-title":"BMC Canc"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib59","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10549-010-0769-3","article-title":"Adjuvant systemic therapy for breast cancer in BRCA1\/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer","volume":"123","author":"Reding","year":"2010","journal-title":"Breast Canc Res Treat"},{"issue":"6","key":"10.1016\/j.breast.2018.11.005_bib60","first-page":"839","article-title":"Reproductive factors and risk of contralateral breast cancer by BRCA1 and BRCA2 mutation status: Results from the WECARE study","volume":"21","author":"Poynter","year":"2010","journal-title":"Cancer Causes Control"},{"issue":"12","key":"10.1016\/j.breast.2018.11.005_bib61","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(10)70257-6","article-title":"Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial","volume":"11","author":"Cuzick","year":"2010","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib62","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s10549-010-1106-6","article-title":"Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer","volume":"124","author":"Buist","year":"2010","journal-title":"Breast Canc Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib63","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.bjc.6605435","article-title":"Second solid cancers after radiotherapy for breast cancer in SEER cancer registries","volume":"102","author":"Berrington de Gonzalez","year":"2010","journal-title":"Br J Canc"},{"issue":"17","key":"10.1016\/j.breast.2018.11.005_bib64","doi-asserted-by":"crossref","first-page":"6865","DOI":"10.1158\/0008-5472.CAN-09-1355","article-title":"Adjuvant hormonal therapy for breast cancer and risk of hormone receptor-specific subtypes of contralateral breast cancer","volume":"69","author":"Li","year":"2009","journal-title":"Cancer Res"},{"issue":"32","key":"10.1016\/j.breast.2018.11.005_bib65","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1200\/JCO.2009.23.1597","article-title":"Relationship between potentially modifiable lifestyle factors and risk of second primary contralateral breast cancer among women diagnosed with estrogen receptor-positive invasive breast cancer","volume":"27","author":"Li","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib66","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/EDE.0b013e318190eee6","article-title":"Age-specific incidence of breast cancer in breast cancer survivors and their first-degree relatives","volume":"20","author":"Bertelsen","year":"2009","journal-title":"Epidemiology"},{"issue":"14","key":"10.1016\/j.breast.2018.11.005_bib67","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1016\/j.ejca.2009.05.022","article-title":"Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial","volume":"45","author":"Alkner","year":"2009","journal-title":"Eur J Canc"},{"issue":"4","key":"10.1016\/j.breast.2018.11.005_bib68","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ijrobp.2008.02.040","article-title":"Dose to the contralateral breast from radiotherapy and risk of second primary breast cancer in the WECARE study","volume":"72","author":"Stovall","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib69","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-007-9709-2","article-title":"The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in The Netherlands","volume":"110","author":"Schaapveld","year":"2008","journal-title":"Breast Canc Res Treat"},{"issue":"4","key":"10.1016\/j.breast.2018.11.005_bib70","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/sj.bjc.6604228","article-title":"Risk for contralateral breast cancer among carriers of the CHEK2*1100delC mutation in the WECARE Study","volume":"98","author":"Mellemkjaer","year":"2008","journal-title":"Br J Canc"},{"issue":"34","key":"10.1016\/j.breast.2018.11.005_bib71","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.2007.16.0192","article-title":"Roles of radiotherapy and chemotherapy in the development of contralateral breast cancer","volume":"26","author":"Hooning","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/jnci\/djm267","article-title":"Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study","volume":"100","author":"Bertelsen","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.breast.2018.11.005_bib73","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/cncr.22639","article-title":"The safety of breast-conserving therapy in patients with breast cancer aged < or\u00a0= 40 years","volume":"109","author":"van der Leest","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib74","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s10549-006-9446-y","article-title":"Breast cancer risk factors and second primary malignancies among women with breast cancer","volume":"105","author":"Trentham-Dietz","year":"2007","journal-title":"Breast Canc Res Treat"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib75","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2006.06.3024","article-title":"Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation","volume":"25","author":"Schmidt","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib76","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/02841860601034834","article-title":"Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer","volume":"46","author":"Rutqvist","year":"2007","journal-title":"Acta Oncol"},{"issue":"5","key":"10.1016\/j.breast.2018.11.005_bib77","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1158\/1055-9965.EPI-06-1003","article-title":"Reproductive history and risk of second primary breast cancer: the WECARE study","volume":"16","author":"Largent","year":"2007","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib78","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ijrobp.2006.12.011","article-title":"Risk of second malignancies after adjuvant radiotherapy for breast cancer: a large-scale, single-institution review","volume":"68","author":"Kirova","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib79","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/0008-5472.CAN-06-3854","article-title":"Risks for familial and contralateral breast cancer interact multiplicatively and cause a high risk","volume":"67","author":"Hemminki","year":"2007","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib80","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1186\/bcr1668","article-title":"Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study","volume":"9","author":"Broeks","year":"2007","journal-title":"Breast Cancer Res"},{"issue":"5","key":"10.1016\/j.breast.2018.11.005_bib81","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ejca.2006.12.009","article-title":"Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1\/2 families as compared to sporadic breast cancer cases","volume":"43","author":"Brekelmans","year":"2007","journal-title":"Eur J Canc"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib82","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s10549-005-9054-2","article-title":"Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1\/2 patients","volume":"95","author":"Tilanus-Linthorst","year":"2006","journal-title":"Breast Canc Res Treat"},{"issue":"16","key":"10.1016\/j.breast.2018.11.005_bib83","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2005.02.7888","article-title":"Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1\/2-associated stage I\/II breast cancer","volume":"24","author":"Pierce","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib84","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/sj.bjc.6603235","article-title":"Cancer risk after radiotherapy for breast cancer","volume":"95","author":"Levi","year":"2006","journal-title":"Br J Canc"},{"issue":"9","key":"10.1016\/j.breast.2018.11.005_bib85","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1002\/ijc.21536","article-title":"Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update","volume":"118","author":"Gronwald","year":"2006","journal-title":"Int J Canc"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib86","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s10549-005-9118-3","article-title":"Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer","volume":"97","author":"Dignam","year":"2006","journal-title":"Breast Canc Res Treat"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib87","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdj095","article-title":"Survival and prognostic factors in BRCA1-associated breast cancer","volume":"17","author":"Brekelmans","year":"2006","journal-title":"Ann Oncol"},{"issue":"21","key":"10.1016\/j.breast.2018.11.005_bib88","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1093\/jnci\/dji342","article-title":"Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial","volume":"97","author":"Nordenskjold","year":"2005","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.breast.2018.11.005_bib89","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/sj.bjc.6602084","article-title":"Radiation-induced malignancies following radiotherapy for breast cancer","volume":"91","author":"Roychoudhuri","year":"2004","journal-title":"Br J Canc"},{"issue":"23","key":"10.1016\/j.breast.2018.11.005_bib90","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/jnci\/djh321","article-title":"Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen","volume":"96","author":"McCaskill-Stevens","year":"2004","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"11","key":"10.1016\/j.breast.2018.11.005_bib91","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMoa040331","article-title":"A\u00a0randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer","volume":"350","author":"Coombes","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib92","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/sj.bjc.6601042","article-title":"Epidemiologic and molecular risk factors for contralateral breast cancer among young women","volume":"89","author":"Li","year":"2003","journal-title":"Br J Canc"},{"issue":"19","key":"10.1016\/j.breast.2018.11.005_bib93","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/jnci\/djg060","article-title":"Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer","volume":"95","author":"Dignam","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"20","key":"10.1016\/j.breast.2018.11.005_bib94","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1200\/JCO.2002.11.101","article-title":"Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less","volume":"20","author":"Fisher","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"10.1016\/j.breast.2018.11.005_bib95","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/jnci\/93.13.1008","article-title":"Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer","volume":"93","author":"Li","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.breast.2018.11.005_bib96","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/jnci\/93.9.684","article-title":"Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial","volume":"93","author":"Fisher","year":"2001","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"6","key":"10.1016\/j.breast.2018.11.005_bib97","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/1097-0215(20001215)88:6<998::AID-IJC25>3.0.CO;2-0","article-title":"Risk factors and age-incidence relationships for contralateral breast cancer","volume":"88","author":"Vaittinen","year":"2000","journal-title":"Int J Canc"},{"issue":"9245","key":"10.1016\/j.breast.2018.11.005_bib98","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/S0140-6736(00)03258-X","article-title":"Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group","volume":"356","author":"Narod","year":"2000","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.breast.2018.11.005_bib99","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/oxfordjournals.annonc.a010406","article-title":"Second cancers after adjuvant tamoxifen therapy for breast cancer in Japan","volume":"11","author":"Matsuyama","year":"2000","journal-title":"Ann Oncol"},{"issue":"24","key":"10.1016\/j.breast.2018.11.005_bib100","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/jnci\/91.24.2112","article-title":"Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations","volume":"91","author":"Robson","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib101","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1023\/A:1006117220284","article-title":"Tamoxifen and risk of large bowel cancer in women with breast cancer","volume":"53","author":"Newcomb","year":"1999","journal-title":"Breast Canc Res Treat"},{"issue":"6","key":"10.1016\/j.breast.2018.11.005_bib102","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/ejso.1999.0711","article-title":"Clinical and histological predictors of contralateral breast cancer","volume":"25","author":"Kollias","year":"1999","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.breast.2018.11.005_bib103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1023\/A:1006197524405","article-title":"Analyzing prognostic factors in breast cancer using a multistate model","volume":"54","author":"Broet","year":"1999","journal-title":"Breast Canc Res Treat"},{"issue":"9114","key":"10.1016\/j.breast.2018.11.005_bib104","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group","volume":"351","author":"Early Breast Cancer Trialists' Collaborative","year":"1998","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.breast.2018.11.005_bib105","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/88.21.1543","article-title":"Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer","volume":"88","author":"Swedish Breast Cancer Cooperative Group","year":"1996","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib106","first-page":"382","article-title":"A\u00a0population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States)","volume":"7","author":"Cook","year":"1996","journal-title":"Cancer Causes Control"},{"issue":"18","key":"10.1016\/j.breast.2018.11.005_bib107","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/jnci\/87.18.1359","article-title":"Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers","volume":"87","author":"Cook","year":"1995","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.breast.2018.11.005_bib108","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1200\/JCO.1995.13.7.1578","article-title":"Contralateral breast cancer: annual incidence and risk parameters","volume":"13","author":"Broet","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.breast.2018.11.005_bib109","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1993.11.8.1545","article-title":"Contralateral breast cancer: clinical characteristics and impact on prognosis","volume":"11","author":"Healey","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"10.1016\/j.breast.2018.11.005_bib110","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1093\/jnci\/84.16.1245","article-title":"Adjuvant radiotherapy and risk of contralateral breast cancer","volume":"84","author":"Storm","year":"1992","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"12","key":"10.1016\/j.breast.2018.11.005_bib111","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199203193261201","article-title":"Cancer in the contralateral breast after radiotherapy for breast cancer","volume":"326","author":"Boice","year":"1992","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.breast.2018.11.005_bib112","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/oxfordjournals.aje.a116565","article-title":"Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer","volume":"136","author":"Bernstein","year":"1992","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.breast.2018.11.005_bib113","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/oxfordjournals.aje.a116566","article-title":"The genetic epidemiology of second primary breast cancer","volume":"136","author":"Bernstein","year":"1992","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib114","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/02841869209088911","article-title":"Results of the cancer research campaign adjuvant trial for perioperative cyclophosphamide and long-term tamoxifen in early breast cancer reported at the tenth year of follow-up. Cancer research campaign breast cancer trials group","volume":"31","author":"Baum","year":"1992","journal-title":"Acta Oncol"},{"issue":"14","key":"10.1016\/j.breast.2018.11.005_bib115","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/jnci\/83.14.1013","article-title":"Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer","volume":"83","author":"Andersson","year":"1991","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"9606","key":"10.1016\/j.breast.2018.11.005_bib116","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(08)60069-0","article-title":"Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials","volume":"371","author":"Early Breast Cancer Trialists' Collaborative Group","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib117","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ctrv.2014.12.002","article-title":"Diagnostic and therapeutic ionizing radiation and the risk of a first and second primary breast cancer, with special attention for BRCA1 and BRCA2 mutation carriers: a critical review of the literature","volume":"41","author":"Drooger","year":"2015","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.breast.2018.11.005_bib118","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/jama.1995.03530050050031","article-title":"Studies of cancer and radiation dose among atomic bomb survivors. The example of breast cancer","volume":"274","author":"Land","year":"1995","journal-title":"J\u00a0Am Med Assoc"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib119","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1158\/1055-9965.EPI-07-2628","article-title":"Multiple diagnostic X-rays for spine deformities and risk of breast cancer","volume":"17","author":"Ronckers","year":"2008","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.breast.2018.11.005_bib120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13058-015-0608-x","article-title":"Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing","volume":"17","author":"Alkner","year":"2015","journal-title":"Breast Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib121","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/ijc.31051","article-title":"Contralateral breast cancers: independent cancers or metastases?","volume":"142","author":"Begg","year":"2018","journal-title":"Int J Canc"},{"issue":"31","key":"10.1016\/j.breast.2018.11.005_bib122","doi-asserted-by":"crossref","first-page":"31820","DOI":"10.18632\/oncotarget.5569","article-title":"Comparative genomic analysis reveals bilateral breast cancers are genetically independent","volume":"6","author":"Song","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib123","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10549-015-3403-6","article-title":"Exome sequencing of contralateral breast cancer identifies metastatic disease","volume":"151","author":"Klevebring","year":"2015","journal-title":"Breast Canc Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib124","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/1097-0142(19880715)62:2<412::AID-CNCR2820620228>3.0.CO;2-3","article-title":"Risk of contralateral breast cancer. Associations with histologic, clinical, and therapeutic factors","volume":"62","author":"Horn","year":"1988","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.breast.2018.11.005_bib125","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/jnci\/95.13.941","article-title":"Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation","volume":"95","author":"Klaren","year":"2003","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib126","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s10549-013-2588-9","article-title":"Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in The Netherlands","volume":"139","author":"Font-Gonzalez","year":"2013","journal-title":"Breast Canc Res Treat"},{"issue":"2","key":"10.1016\/j.breast.2018.11.005_bib127","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10549-011-1618-8","article-title":"Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses","volume":"130","author":"Vichapat","year":"2011","journal-title":"Breast Canc Res Treat"},{"issue":"6","key":"10.1016\/j.breast.2018.11.005_bib128","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/SLA.0000000000000769","article-title":"Contralateral prophylactic mastectomy after unilateral breast cancer: a systematic review and meta-analysis","volume":"260","author":"Fayanju","year":"2014","journal-title":"Ann Surg"},{"issue":"9804","key":"10.1016\/j.breast.2018.11.005_bib129","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(11)61629-2","article-title":"Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials","volume":"378","author":"Group","year":"2011","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.breast.2018.11.005_bib130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/obr.12190","article-title":"Weight loss intervention trials in women with breast cancer: a systematic review","volume":"15","author":"Reeves","year":"2014","journal-title":"Obes Rev"},{"issue":"3","key":"10.1016\/j.breast.2018.11.005_bib131","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12609-013-0113-0","article-title":"Weight loss intervention for breast cancer survivors: a systematic review","volume":"5","author":"Playdon","year":"2013","journal-title":"Curr Breast Cancer Rep"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977618303229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977618303229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:41:20Z","timestamp":1760776880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977618303229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":131,"alternative-id":["S0960977618303229"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2018.11.005","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}